---
document_datetime: 2023-09-21 19:28:46
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/zoledronic-acid-teva-pharma-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: zoledronic-acid-teva-pharma-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.9032892
conversion_datetime: 2025-12-26 16:54:06.610325
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

## Zoledronic acid Teva Pharma

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                          | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on no   | Product Information affected 3   | Summary                                                                                                                                                                                                                                                                                   |
|----------------------|------------------------------------------------------------------------------------------------|-------------------------------------|------------------------------------------------|----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R/0014               | Renewal of the marketing authorisation.                                                        | 23/03/2017 product                  | 22/05/2017                                     | SmPC, Annex II, Labelling and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Zoledronic acid Teva Pharma in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |
| IAIN/0013            | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation | 14/12/2015                          | 15/07/2016                                     | SmPC and PL                      |                                                                                                                                                                                                                                                                                           |

<!-- image -->

Medicinal product no longer authorised

<!-- image -->

<div style=\"page-break-after: always\"></div>

| IB/0012   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                                                                                                                                                                                                                        | 10/08/2015   | 15/07/2016    | SmPC, Annex II and PL   |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|---------------|-------------------------|
| IA/0011   | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient                                                                                                                                                                                                                                                                                                                                                        | 09/04/2015   | n/a           | longer authorised       |
| IB/0010   | To update SmPC sections 4.1, 4.3, 4.8 and 5.1 to extend the indication to also include those with a recent low-trauma hip fracture I line with the originator. The PL is updated accordingly. Furthermore minor editorial changes have been implemented in the HU annexes to bring them in line with the originator. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH Medicinal product | 26/03/2015   | 05/05/2015 no | SmPC and PL             |
| T/0009    | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 08/12/2014   | 19/12/2014    | SmPC, Labelling and PL  |

<div style=\"page-break-after: always\"></div>

| IB/0008   | Update of SmPC section 4.2 to place the information on hydration and calcium intake to the beginning of the section instead of under the subheading Paget`s disease. And update of sections 4.4 and 4.8 of the SmPC to clarify that reporting of osteonecrosis of the jaw is not limited to cancer patients, and to add 'anti-angiogenic medicinal products\" to the concomitant risk factors for ONJ, according to the reference product. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH   | 06/08/2014   | 19/12/2014           | SmPC authorised                  |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|----------------------|----------------------------------|
| IB/0007   | B.II.f.1.a.1 - Stability of FP - Reduction of the shelf life of the finished product - As packaged for sale                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 25/04/2014   | 19/12/2014 no longer | SmPC                             |
| IB/0006   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH product                                                                                                                                                                                                                                                                                                                                                                                                                                     | 08/11/2013   | 20/11/2013           | SmPC, Annex II, Labelling and PL |
| IA/0005/G | This was an application for a group of variations. B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its Medicinal                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 09/08/2013   | n/a                  |                                  |

<div style=\"page-break-after: always\"></div>

|           | corresponding test method B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method   |            |               | authorised             |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|---------------|------------------------|
| IAIN/0003 | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                          | 22/05/2013 | n/a           | longer                 |
| IB/0002   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH                                                                                                                                                                                                                          | 29/01/2013 | 20/11/2013 no | SmPC and PL            |
| IB/0001   | B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes product                                                                                                                                                                                                                                                             | 08/11/2012 | 20/11/2013    | SmPC, Labelling and PL |

Medicinal product no longer authorised